Released in 2016 for the detection of most relevant carbapenemase groups as well as vancomycin resistance markers from pure culture samples, the Amplidiag® CarbaR+VRE diagnostic test is now also validated on stool samples and rectal swabs.
Released in 2016 for the detection of most relevant carbapenemase groups as well as vancomycin resistance markers from pure culture samples, the Amplidiag® CarbaR+VRE diagnostic test is now also validated on stool samples and rectal swabs. The test identifies in one single test the most clinically relevant carbapenemase-producing organisms (CPO) and vancomycin-resistant Enterococci (VRE).
Learn more about Amplidiag® CarbaR+VRE.
